Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.

Context: Controversy exists whether serotonin-norepinephrine reuptake inhibitors (SNRIs) have improved efficacy compared with selective serotonin reuptake inhibitors (SSRIs). Objective: To compare clinical outcomes of adults treated with SSRIs or SNRIs for major depressive disorder (MDD) under ideal...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 35; no. 2; pp. 177 - 189
Autores principales: Machado M, Einarson TR
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Wiley-Blackwell Apr2010
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105140058&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105140058
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Apr2010
      vid: 35
      iid: 2
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        105140058
        2010588234
        10.1111/j.1365-2710.2009.01050.x
        NLM20456736
        105140058
      ppf: 177
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.
      aug:
        au:
          Machado M
          Einarson TR
        affil: Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto, Toronto, ON, Canada
      sug:
        subj:
          Adrenergic Uptake Inhibitors
          Depression Drug Therapy
          Norepinephrine
          Serotonin Uptake Inhibitors Administration and Dosage
          Clinical Trials
          Cochrane Library
          Confidence Intervals
          Disease Remission
          Embase
          Funding Source
          Human
          Medline
          Meta Analysis
          Odds Ratio
          Treatment Outcomes
      ab: Context: Controversy exists whether serotonin-norepinephrine reuptake inhibitors (SNRIs) have improved efficacy compared with selective serotonin reuptake inhibitors (SSRIs). Objective: To compare clinical outcomes of adults treated with SSRIs or SNRIs for major depressive disorder (MDD) under ideal clinical condition, research design, and outcome measure. Data sources: Electronic databases searched were Medline, Embase and Cochrane Library from inception to July 2007. Study selection: Included studies were those head-to-head randomized trials comparing remission (HAMD-17 <=7-8, MADRS <=10-12) after 8-12 weeks of therapeutic doses of SSRIs or SNRIs in patients diagnosed with MDD were targeted for analysis. Reviews, letters, commentaries, economic studies, etc. were excluded. Studies were reviewed by two independent researchers. Where disagreements occurred in study selection, a consensus approach was used. Data extraction and analysis: Targeted outcome data included number of patients achieving remission, withdrawing from therapy due to lack of efficacy (LoE) and/or adverse drug reactions (ADRs), and total patients in trial. A random effects model combined intent-to-treat (ITT) and per-protocol (PP) odds ratio (OR), and remission and dropout rates. Chi-square assessed heterogeneity. Quality assessment was done using Downs-Black checklist. Results: Thirty-three studies were identified; 18 were rejected (patients had co-morbidities in 7, outcomes differed in 5, different follow-up in 3, and three reviews). Fifteen head-to-head trials of 3094 patients, average age was 41·9 ± 11·9 years (for SNRIs) and 41·6 ± 12·1 years (for SSRIs), P = 0·941. All analyses displayed non-heterogeneity ( P > 0·05). The OR (under ITT) was 1·27 (1·06-1·52 95% CI) favoring SNRIs. Meta-analytic remission rates were 48·5 ± 3·2% and 41·9 ± 4·2% for SNRIs and SSRIs, respectively. The meta-analytic difference in remission rates between drugs was 5·7% ( P = 0·007). Dropout rates due to ADRs were higher with SNRIs than SSRIs (3·2% difference, P < 0·001). Dropout rates due to LoE were non-significant between studied groups ( P > 0·05). Conclusions: Serotonin and norepinephrine reuptake inhibitors showed statistical but not clinical significance when compared with SSRIs in treating MDD.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N